迈威生物：赴香港上市获中国证监会备案通知书，中信证券、海通国际联席保荐

Core Viewpoint - Maiwei Biotech (688062.SH) has received approval from the China Securities Regulatory Commission for an overseas listing, allowing it to issue up to 62.6646 million shares on the Hong Kong Stock Exchange [1][3]. Group 1 - Maiwei Biotech submitted its prospectus to the Hong Kong Stock Exchange on January 6, 2025, and August 29, 2025, with CITIC Securities and Haitong International as joint sponsors [3]. - The company was listed on the A-share market on January 18, 2022, with a stock code of 688062.SH, and as of November 20, 2025, its total market capitalization was approximately RMB 16.7 billion [3].